Articles tagged with Target Proteins
A study published in Science Advances reveals a mechanism to bind to intrinsically disordered proteins, providing a new approach for therapeutic design. The research, led by Dr. Xavier Salvatella, shows that these proteins adopt more organized conformations when clustering, allowing for selective binding by a drug.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers have identified ALPK2 as a potential therapeutic target for treating heart failure with preserved ejection function (HFpEF). The enzyme is believed to prevent stiff heart conditions through regulating the TPM1 gene. This discovery offers new hope for developing treatment options targeting ALPK2.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
Researchers at U of T have created SIMPL2, a platform that simplifies detection and improves accuracy of protein-protein interactions. The tool enables the rapid identification of protein interactions, including weak ones, for targeted drug therapies.
Researchers found effective peptidomimetics that can bind to and inhibit Aurora-A's interaction with TACC3 without inhibiting its enzymatic function. This inhibition also showed promise in targeting a different protein-protein interaction between N-Myc and Aurora-A, which is crucial in childhood brain cancers.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
A team of researchers from the University of Bonn has trained a chemical language model to predict potential active ingredients with special properties. The AI was able to reproduce the chemical structures of compounds with known dual-target activity, which may be effective in treating various diseases.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
Researchers at Uppsala University used AI to predict the three-dimensional structure of a receptor, identifying molecules that bind to it with higher accuracy than traditional methods. This breakthrough accelerates the development of new drugs for mental health disorders such as schizophrenia and depression.
A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.
A study published in PNAS reveals that ETV5 enhances the expression of osteopontin, leading to the differentiation of T cells into follicular helper cells. In SLE patients, disease activity is proportional to ETV5 and osteopontin levels, suggesting a potential therapeutic target for treating lupus.
Researchers at Baylor College of Medicine identified new potential therapeutic targets for cancer using a comprehensive approach that integrated proteomics, genomics, and epigenomics data from 10 cancer types. The study validated many protein and small protein or peptide targets as promising candidates for therapeutic strategies.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers created a corticolimbic index tool that categorizes Alzheimer's disease into three subtypes based on brain changes. The study found demographic and clinical differences among sex, age at onset, and rate of cognitive decline.
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins. The study identified over 600 new effector proteins that could be used therapeutically, including those that can efficiently degrade or stabilize target proteins.
Researchers have developed a new way to visualize the smallest protein clusters using CluMPS, a molecular tool that activates when target protein clusters are present. This technology promises to be a foundational advancement in detecting disease-causing protein clusters and understanding protein functioning.
Researchers have identified macrocyclic compounds as a potential solution for targeting proteins critical to tumorigenesis, blocking nearly 80% of cancer's signature characteristic events. Additionally, these small compact molecules can effectively overcome drug resistance by binding to mutant proteins and inhibiting their activities.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Researchers at the University of California San Diego have created modular nanoparticles that can be tailored for various applications, including targeted drug delivery and neutralizing biological agents. By leveraging a plug-and-play approach, scientists can rapidly modify functional biological nanoparticles with ease.
Engineers developed a nanoparticle vaccine targeting S100A9, a protein that attracts cancer cells to the lungs. The vaccine significantly reduced lung tumor growth and improved survival rates in mice with metastatic breast cancer after surgery.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
An international team has decoded the TSPO protein to visualize neuroinflammation, revealing its relationship with microglial cells. The study's findings pave the way for optimizing observation of neuroinflammatory processes and re-reading previous studies.
A new study published in eLife reveals the folding speed limit of helical membrane proteins using a robust single-molecule tweezer method. The findings provide unprecedented insights into structural states, kinetics, and energy barrier properties, offering valuable guidance for advancing pharmaceutical research and design.
A new nano-sized force sensor developed by Tampere University researchers allows for the measurement of intracellular forces and mechanical strains. This technology has great potential for studying cancer cells and understanding cellular mechanics.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
A novel database, CycPeptMPDB, has been created to facilitate the development of drugs based on cyclic peptides. The database contains information on thousands of cyclic peptides and their membrane permeability values, enabling researchers to select candidate peptides that can penetrate human cell membranes.
Seer researchers identified four structurally distinct protein isoforms that were differentially expressed in non-small cell lung cancer patients. These findings suggest that these protein isoforms may play a role in NSCLC disease pathogenesis, potentially leading to the development of new diagnostic markers or therapeutic targets.
Researchers discovered polyphenol PCB2DG reduces inflammatory responses by inhibiting glutamine uptake in CD4+ T cells, promoting gene expression to synthesize amino acids. The study's findings offer potential for dietary polyphenol treatment of autoimmune diseases.
The addition of antioxidants to cell cultures can improve the production of monoclonal antibodies by reducing oxidative stress and increasing cell viability. This has potential benefits for therapies targeting cancer and autoimmune diseases.
Researchers at Nagoya University have identified 2,6-dihalopurines as a new class of stomatal opening inhibitors, potentially involving LRX3-5 and RALF peptide. This discovery may lead to the development of new agrochemicals and chemical biology research applications.
Researchers utilized the Chemistry42 platform to generate novel molecular structures and identified a hit molecule for CDK20, a promising target for hepatocellular carcinoma. The platform's customizable reward function and generative models enabled efficient design and optimization of molecules.
Researchers highlight CD200's role in regulating immunosuppressive tumor microenvironments and propose alternative strategies for its neutralization. Unbiased genomic- and proteomic-based approaches may help clarify CD200 expression regulation across various human cancers.
A new serological test, PepSeq, allows scientists to quickly test antibody binding against hundreds of thousands of protein targets, helping prepare for and respond to pandemics. The technology identifies specific antibodies that provide protection against infection, holding promise for developing effective vaccines and treatments.
Researchers at Texas A&M University engineered DARPins to block the interaction between the COVID-19 virus and host cells, significantly reducing disease progression. The nasal sprays showed effectiveness against various variants, including omicron, and could provide a lower-cost therapeutic option for those at high risk.
Researchers identified specific immune cells driving deadly heart inflammation in cancer immunotherapy patients, and found that CD8 T cells target the heart muscle. The study's findings have led to investigations into preventing or treating this form of myocarditis, a common but fatal side effect of ICIs.
A study by CeMM researchers and the University of Dundee identifies mutations in E3 ligases that mediate resistances in cell cultures, but also finds that these mutations can be targeted by chemically modified degraders. This understanding has clinical relevance and enables further improvement of cancer therapy drugs.
Researchers uncover critical shape-change in cereblon protein that CELMoD drugs must cause to work effectively. The finding enables the development of more effective cancer-fighting treatments.
A new study reveals that different SCLC subtypes have specific molecular characteristics, leading to varying responses to cancer treatment. The research provides a basis for developing targeted and personalized treatment approaches tailored to each subtype.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
Researchers developed an engineered Cas13 system that detects SARS-CoV-2 in biological samples with high sensitivity and speed. The new platform outperforms traditional PCR testing, finding 10 out of 11 positives and no false positives in clinical samples.
Researchers developed an AI-based screening method that models drug and target protein interactions using natural language processing techniques. The technique achieved high accuracy in identifying promising drug candidates, which can accelerate the exploration of new medicines and repurpose existing ones.
A team of researchers has designed in silico molecular probes to track the progress of a misbehaving protein linked to neurodegenerative diseases like ALS and FTD. The probes can detect TDP-43 aggregates at high resolution, paving the way for early diagnosis.
A study at Washington State University has identified sulfatase-2 as a critical protein driving damage caused by rheumatoid arthritis. The discovery sheds light on molecular processes behind inflammation in the disease and could lead to improved treatments.
A study suggests that adopting the DASH diet may have the greatest impact on reducing cardiovascular disease among people with stage 1 hypertension. The research estimates that this lifestyle change could prevent 15,000 heart disease events among men and 11,000 among women.
A new study by Marshall University researchers found that inhibiting Na+/K+ ATPase alpha 1 subunit proteins dramatically inhibited in vivo thrombosis in male mice. The study suggests that targeting this protein could lead to a novel anti-thrombotic therapy with fewer side effects.
A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.
A study by CNIC scientists has identified a key role for the MKK3/6–p38γ/δ signaling pathway in cardiac hypertrophy. Inhibition of p38α promotes an unexpected activation of the other branch of the pathway, consisting of the proteins MKK3, p38γ, and p38δ. This activation induces another key pathway in cardiac hypertrophy, the mTOR pathway.
Researchers used x-ray crystallography to study the main protease of SARS-CoV-2 at various temperatures, revealing subtle conformational changes and potential targets for drug design. These findings may inspire the development of new antiviral drugs to counteract COVID-19 and prevent future pandemics.
University of Cincinnati researchers are studying whether targeting an inflammation pathway can improve patient results for soldiers with burn injuries combined with traumatic brain injuries. The research focuses on a specific protein that causes inflammation, which can lead to complications such as anemia and death.
SLFN11 acts as a surveillance factor for protein homeostasis by alleviating proteotoxic stress derived from protein synthesis and maturation. Its lack makes cells vulnerable to anticancer drugs inducing ER and proteotoxic stress, leading to chemoresistance. SLFN11 is also involved in regulating immune response and inflammation.
Research suggests that chemicals produced by gut microbes after eating red meat may contribute to cardiovascular disease. The study found a 22% higher risk of atherosclerotic cardiovascular disease associated with increased red meat consumption, which was partly attributed to elevated levels of TMAO and related metabolites in the blood.
Researchers at Arizona State University have discovered molecular signatures associated with acute and chronic phases of traumatic brain injury (TBI). The study aims to address current limitations in TBI diagnosis and treatment by identifying biomarkers and understanding the blood-brain barrier's role in drug delivery.
Gladstone researchers discovered that BET proteins play two distinct roles in interacting with SARS-CoV-2 infected human cells: giving the virus a window into cells while helping our cells defend themselves. Blocking certain BET proteins worsens disease symptoms, highlighting the need for targeted therapeutics.
Researchers used deactivated Cas9 proteins to target key segments of the human genome and synthetically trigger gene transcription. The study revealed that enhancers can send messages in both directions, but with a predominant regulatory mode where an enhancer tracks toward corresponding promoters.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.